These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. The Conundrum of Dedifferentiation in a Liposarcoma at a Peculiar Location: A Case Report and Literature Review. Ciongariu AM; Dumitru AV; Cîrstoiu C; Crețu B; Sajin M; Țăpoi DA; Ciobănoiu AD; Bejenariu A; Marin A; Costache M Medicina (Kaunas); 2023 May; 59(5):. PubMed ID: 37241198 [TBL] [Abstract][Full Text] [Related]
46. A cryptic EWSR1::DDIT3 fusion in myxoid liposarcoma: Potential pitfalls with FISH and cytogenetics. Ibstedt S; de Mattos CBR; Köster J; Mertens F Genes Chromosomes Cancer; 2023 Mar; 62(3):167-170. PubMed ID: 36379683 [TBL] [Abstract][Full Text] [Related]
47. [Myxiod pleomorphic liposarcoma: a clinicopathological and molecular genetic analysis of six cases]. Zheng XC; Huang HJ; You J; Lin XY; Chen DR; Zhong D Zhonghua Bing Li Xue Za Zhi; 2022 Aug; 51(8):738-742. PubMed ID: 35922164 [No Abstract] [Full Text] [Related]
48. FUS-DDIT3 Fusion Protein-Driven IGF-IR Signaling is a Therapeutic Target in Myxoid Liposarcoma. Trautmann M; Menzel J; Bertling C; Cyra M; Isfort I; Steinestel K; Elges S; Grünewald I; Altvater B; Rossig C; Fröhling S; Hafner S; Simmet T; Åman P; Wardelmann E; Huss S; Hartmann W Clin Cancer Res; 2017 Oct; 23(20):6227-6238. PubMed ID: 28637688 [No Abstract] [Full Text] [Related]
49. Deciphering the role of FUS::DDIT3 expression and tumor microenvironment in myxoid liposarcoma development. Ranji P; Jonasson E; Andersson L; Filges S; Luna Santamaría M; Vannas C; Dolatabadi S; Gustafsson A; Myklebost O; Håkansson J; Fagman H; Landberg G; Åman P; Ståhlberg A J Transl Med; 2024 Apr; 22(1):389. PubMed ID: 38671504 [TBL] [Abstract][Full Text] [Related]
50. Myxoid liposarcoma FUS-DDIT3 fusion oncogene induces C/EBP beta-mediated interleukin 6 expression. Göransson M; Elias E; Ståhlberg A; Olofsson A; Andersson C; Aman P Int J Cancer; 2005 Jul; 115(4):556-60. PubMed ID: 15688424 [TBL] [Abstract][Full Text] [Related]
51. The FUS-DDIT3 Interactome in Myxoid Liposarcoma. Yu JSE; Colborne S; Hughes CS; Morin GB; Nielsen TO Neoplasia; 2019 Aug; 21(8):740-751. PubMed ID: 31220736 [TBL] [Abstract][Full Text] [Related]
52. Translocations and amplifications of chromosome 12 in liposarcoma demonstrated by the LSI CHOP breakapart rearrangement probe. Willmore-Payne C; Holden J; Turner KC; Proia A; Layfield LJ Arch Pathol Lab Med; 2008 Jun; 132(6):952-7. PubMed ID: 18517278 [TBL] [Abstract][Full Text] [Related]
53. Vulvar Myxoid Liposarcoma and Well Differentiated Liposarcoma With Molecular Cytogenetic Confirmation: Case Reports With Review of Malignant Lipomatous Tumors of the Vulva. Schoolmeester JK; Leifer AJ; Wang L; Hameed MR Int J Gynecol Pathol; 2015 Jul; 34(4):390-5. PubMed ID: 25851712 [TBL] [Abstract][Full Text] [Related]
54. DDIT3/CHOP and the sarcoma fusion oncoprotein FUS-DDIT3/TLS-CHOP bind cyclin-dependent kinase 2. Bento C; Andersson MK; Aman P BMC Cell Biol; 2009 Dec; 10():89. PubMed ID: 20017906 [TBL] [Abstract][Full Text] [Related]
55. Establishment and characterization of NCC-MLPS1-C1: a novel patient-derived cell line of myxoid liposarcoma. Noguchi R; Yoshimatsu Y; Sei A; Hirabayashi K; Ozawa I; Kikuta K; Kondo T Hum Cell; 2021 Mar; 34(2):667-674. PubMed ID: 33146842 [TBL] [Abstract][Full Text] [Related]
56. Benign recurring lipoblastoma in an adult versus well differentiated subcutaneous myxoid liposarcoma: clinicopathologic, immunohistochemical and molecular analysis of a unique case. Silverman JS; Hamilton J; Tamsen A Pathol Res Pract; 1999; 195(11):787-92; discussion 793. PubMed ID: 10605700 [TBL] [Abstract][Full Text] [Related]